Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ParadigMM-1B of AMG 701 in relapsed/refractory multiple myeloma
NL-OMON52671Phase 1Completed
- Sponsor
- Amgen
- Start
- Apr 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of pavurutamab, pomalidomide and dexamethasone in multiple myeloma (MM) (4 arms), sponsored by Amgen. Primary endpoints: Dose-limiting toxicities and safety, Safety and tolerability at RP2D and 1 more. Started Apr 2018; status: completed.
02
Drugs
pavurutamabpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON52671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52671.